Literature DB >> 3263373

Regulation of pim and myb mRNA accumulation by interleukin 2 and interleukin 3 in murine hematopoietic cell lines.

F Dautry1, D Weil, J Yu, A Dautry-Varsat.   

Abstract

We have studied the mRNA accumulation of pim and myb genes in two interleukin 2- (IL2-)dependent, CTLL-2 and B6.1, and one IL3-dependent, FDC-P2, murine hematopoietic cell lines. To be able to dissociate the IL2 response from the phenomenon of lymphocyte activation, we used cell lines constitutively expressing the high affinity IL2 receptor. Deprivation of IL2 for 16 h led to an accumulation of CTLL-2 cells in G0/G1, and stimulation with IL2 induced a progression in S phase after 10 h. An increased accumulation of pim mRNA was observed in all cases in response to IL2 or IL3. This regulation did not require de novo protein synthesis and was, in CTLL-2 cells, mostly at the transcriptional level. Expression of myb was more complex: in CTLL-2 and FDC-P2 it is high and constitutive, while in B6.1 it is low and induced by IL2. This difference in myb regulation correlates with the higher level of myb expression in immature cells, as only B6.1 is functionally mature. Furthermore, it shows that transcription of myb does not affect the control of the cell cycle by the growth factors IL2 and IL3. These studies demonstrate that pim belongs to the small group of protooncogenes that can be induced during the primary response to growth factors (fos, myc, and myb) and that constitutive expression of myb, at least at the RNA level, is not sufficient to abrogate the growth factor requirement of hematopoietic cell lines.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263373

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Prolactin-regulated pim-1 transcription: identification of critical promoter elements and Akt signaling.

Authors:  Nithya Krishnan; Huiqi Pan; Donna J Buckley; Arthur Buckley
Journal:  Endocrine       Date:  2003 Feb-Mar       Impact factor: 3.633

2.  In vivo kinetics of mRNA splicing and transport in mammalian cells.

Authors:  A Audibert; D Weil; F Dautry
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

3.  Defective retroviruses can disperse in the human genome by intracellular transposition.

Authors:  T Tchenio; T Heidmann
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

4.  Characterization of the testes-specific pim-1 transcript in rat.

Authors:  D Wingett; R Reeves; N S Magnuson
Journal:  Nucleic Acids Res       Date:  1992-06-25       Impact factor: 16.971

5.  Pim3 negatively regulates glucose-stimulated insulin secretion.

Authors:  Gregory Vlacich; Martijn C Nawijn; Gene C Webb; Donald F Steiner
Journal:  Islets       Date:  2010-09-01       Impact factor: 2.694

6.  Isolation of interleukin 2-induced immediate-early genes.

Authors:  C Beadling; K W Johnson; K A Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

Review 7.  PIM1: a promising target in patients with triple-negative breast cancer.

Authors:  Wen Zhao; RuiYue Qiu; Pan Li; Jin Yang
Journal:  Med Oncol       Date:  2017-07-18       Impact factor: 3.064

8.  Expression of human pim family genes is selectively up-regulated by cytokines promoting T helper type 1, but not T helper type 2, cell differentiation.

Authors:  Teija L T Aho; Riikka J Lund; Emmi K Ylikoski; Sampsa Matikainen; Riitta Lahesmaa; Päivi J Koskinen
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

Review 9.  Recent advances in the understanding of interleukin-2 signal transduction.

Authors:  F Gesbert; M Delespine-Carmagnat; J Bertoglio
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

10.  Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor alpha-chain expression.

Authors:  Wei Liao; Dustin E Schones; Jangsuk Oh; Yongzhi Cui; Kairong Cui; Tae-Young Roh; Keji Zhao; Warren J Leonard
Journal:  Nat Immunol       Date:  2008-09-28       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.